← CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ)
Biological Products, (No Diagnostic Substances) · market cap $6M · as of 2026-10-27
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-06 (est.)
Earnings
Pipeline
2
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Creative Medical Technology Holdings (CELZ) is a micro-cap biological products company with 4 employees, a market cap of about $5M (~6.59M shares at ~$0.71) and no reported revenue in 2021-2025. Our data lists two Phase 2 programs, CELZ-201 Administration in Type 1 Diabetes (lead) and CELZ-201-DDT in Chronic Low-back Pain. The stock trades at roughly 0.5x the $8.7M of cash on the balance sheet, with an estimated Phase 2 event on our calendar for 2027-01-31.
The catalyst path
- 2026-11-06 (est.)Earningsimp 5/10
- 2027-01-31 (est.)Phase 2 · CELZ-201 Administrationimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| CELZ-201 Administration | Phase 2 | Type 1 Diabetes |
| CELZ-201-DDT | Phase 2 | Chronic Low-back Pain |
Price & technical context
3-month
+0.0%
6-month
-69.1%
12-month
-85.9%
52-wk range
$0.65–$5.59
vs 50-day MA
-28.0%
vs 200-day MA
-56.7%
Realized vol
135.2%
Max drawdown
-89.9%
Daily closes through 2026-10-27. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for CELZ (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.